LIGAND PHARMACEUTICALS INC Quarterly Debt-to-equity in % from Q1 2013 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Ligand Pharmaceuticals Inc quarterly Debt-to-equity history and growth rate from Q1 2013 to Q2 2024.
  • Ligand Pharmaceuticals Inc Debt-to-equity for the quarter ending June 30, 2024 was 13.1 %, a 45.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 13.1 -11 -45.8% Jun 30, 2024
Q1 2024 13.7 -15.6 -53.3% Mar 31, 2024
Q4 2023 16.6 -16.1 -49.2% Dec 31, 2023
Q3 2023 20.4 -19.8 -49.2% Sep 30, 2023
Q2 2023 24.1 -23.1 -48.9% Jun 30, 2023
Q1 2023 29.3 -24.3 -45.3% Mar 31, 2023
Q4 2022 32.7 -29.1 -47% Dec 31, 2022
Q3 2022 40.1 -29.8 -42.6% Sep 30, 2022
Q2 2022 47.2 -28.4 -37.5% Jun 30, 2022
Q1 2022 53.5 -27.2 -33.7% Mar 31, 2022
Q4 2021 61.8 -20.5 -24.9% Dec 31, 2021
Q3 2021 69.9 -13.4 -16.1% Sep 30, 2021
Q2 2021 75.6 -8.36 -9.96% Jun 30, 2021
Q1 2021 80.7 -0.83 -1.02% Mar 31, 2021
Q4 2020 82.3 +1.54 +1.91% Dec 31, 2020
Q3 2020 83.3 -1.42 -1.68% Sep 30, 2020
Q2 2020 83.9 -25.5 -23.3% Jun 30, 2020
Q1 2020 81.6 -59.6 -42.2% Mar 31, 2020
Q4 2019 80.7 -71.8 -47.1% Dec 31, 2019
Q3 2019 84.7 -58.7 -40.9% Sep 30, 2019
Q2 2019 109 +5.11 +4.9% Jun 30, 2019
Q1 2019 141 +82.6 +141% Mar 31, 2019
Q4 2018 153 +91.6 +150% Dec 31, 2018
Q3 2018 143 +81.4 +131% Sep 30, 2018
Q2 2018 104 +40.1 +62.4% Jun 30, 2018
Q1 2018 58.6 -7.8 -11.7% Mar 31, 2018
Q4 2017 61 -5.05 -7.65% Dec 31, 2017
Q3 2017 61.9 -9.16 -12.9% Sep 30, 2017
Q2 2017 64.2 -11 -14.6% Jun 30, 2017
Q1 2017 66.4 -30.9 -31.8% Mar 31, 2017
Q4 2016 66.1 -85.6 -56.4% Dec 31, 2016
Q3 2016 71.1 -163 -69.6% Sep 30, 2016
Q2 2016 75.3 -456 -85.8% Jun 30, 2016
Q1 2016 97.3 -332 -77.4% Mar 31, 2016
Q4 2015 152 -119 -43.9% Dec 31, 2015
Q3 2015 234 +71.8 +44.3% Sep 30, 2015
Q2 2015 532 +447 +528% Jun 30, 2015
Q1 2015 430 +323 +301% Mar 31, 2015
Q4 2014 270 +124 +85.1% Dec 31, 2014
Q3 2014 162 -24 -12.9% Sep 30, 2014
Q2 2014 84.6 -155 -64.7% Jun 30, 2014
Q1 2014 107 -214 -66.6% Mar 31, 2014
Q4 2013 146 Dec 31, 2013
Q3 2013 186 Sep 30, 2013
Q2 2013 240 Jun 30, 2013
Q1 2013 321 Mar 31, 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.